common cold
Conditions
Interventions
test group:Siji Antiviral mixture
placebo group :Siji Antiviral mixture Simulant agent
Sponsors
China Japan Friendship Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) Conform to the diagnosis of acute upper respiratory tract infection (common cold) in Western medicine; (2) Within 48 hours from the onset of the onset to the entry into the group; (3) After the onset, the body temperature of the armpit is 37.5?.
Exclusion criteria
Exclusion criteria: (1) Combined with influenza, pneumonia, new coronavirus pneumonia, suppurative tonsillitis, acute tracheo-bronchitis, bronchiectasis, tuberculosis, primary ciliary dyskinesia syndrome, other acute nasal diseases (such as allergic rhinitis) , acute and chronic rhinitis, acute and chronic sinusitis, etc.), abnormal nasal mucosal function who have undergone nasal surgery or nasopharyngeal radiotherapy; (2) The total number of white blood cells in the blood is greater than 1.1 times the upper limit of the normal reference value; (3) During the course of the disease, other internal medicines for the disease (such as cold medicine, antiviral drugs, antibiotics, traditional Chinese medicines, etc.) should be used for more than 1 day before treatment; antipyretic and analgesic drugs should be used within 24 hours before entering the group; (4) BMI=30kg/m2 [BMI=weight (kg)/height (m)2]; (5) Combination of serious primary diseases of the heart, brain, lung, liver, kidney and blood system, such as viral hepatitis, hemophilia, mental illness, etc.; (6) Women who are pregnant or planning to become pregnant, lactating women, patients of childbearing age who are unable or unwilling to take adequate contraception during the trial, or their spouses unwilling to take contraceptive measures; (7) Allergic constitution, if there is a history of allergy to two or more drugs or food, or known allergy to each component of the research drug; (8) Participate in or are participating in clinical trials of other drugs within 3 months; (9) The investigator believes that it is not suitable to participate in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to disappearance of all and single symptoms;The disappearance rate of all and single symptoms at different time points after treatment;Antipyretic time;The rate of normalization of body temperature at different time points after treatment;Changes in clinical symptom scores;Clinical efficacy of colds;emergency medication use; | — |
Countries
China
Contacts
Public ContactMa an lin
China Japan Friendship Hospital
Outcome results
None listed